Research analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Price Performance
Pulmatrix stock opened at $2.14 on Tuesday. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $2.75. The firm’s 50 day moving average price is $2.10 and its 200-day moving average price is $1.99. The stock has a market cap of $7.82 million, a P/E ratio of -0.89 and a beta of 0.99.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The company had revenue of $1.55 million during the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- Low PE Growth Stocks: Unlocking Investment Opportunities
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- What is the NASDAQ Stock Exchange?
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- What Are the FAANG Stocks and Are They Good Investments?
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
